Second Quarter 2026
Filed Aug 13, 2026Record revenue, with Q2 2026 product sales of $37.6 million, representing 99% growth over Q2 2025; raising 2026 revenue guidance to exceed $145 million.
Second-quarter revenue rose 99% year over year to $37.6 million, the company generated GAAP net income of $11.6 million and Adjusted EBITDA of $16.2 million, and management raised both revenue and Adjusted EBITDA margin guidance.
Key metrics
as reported| Metric | Value | q/q | y/y |
|---|---|---|---|
| Total net revenueGAAP | $37.6 million | – | 99% |
| Product sales, netGAAP | $ 37,589 | – | – |
| Gross profitGAAP | $25.4 million | – | 113% |
| Adjusted gross profitnon-GAAP | $27.4 million | – | – |
| Adjusted gross marginnon-GAAP | 73% | – | – |
| Research and development expensesGAAP | $1.0 million | – | – |
| General and administrative expensesGAAP | $11.6 million | – | 20% |
| Adjusted general and administrative expensenon-GAAP | $10.2 million | – | – |
| Total operating expensesGAAP | $ 12,619 | – | – |
| Income from operationsGAAP | $ 12,794 | – | – |
| EBITDAnon-GAAP | $14.1 million | – | – |
| Adjusted EBITDAnon-GAAP | $16.2 million | – | – |
| Adjusted EBITDA marginnon-GAAP | 43% of revenue | – | – |
| Net incomeGAAP | $11.6 million | – | – |
| Net income per share, basicGAAP | $0.42 | – | – |
| Net income per share, dilutedGAAP | $0.35 | – | – |
| Non-GAAP net incomenon-GAAP | $14.3 million | – | – |
| Non-GAAP earnings per share, basicnon-GAAP | $0.52 | – | – |
| Non-GAAP earnings per share, dilutednon-GAAP | $0.43 | – | – |
| Six-month total net revenuesGAAP | $ 61,855 | – | – |
| Six-month net incomeGAAP | $ 13,132 | – | – |
Full year 2026 outlook
- Revenueexceed $145 million
- Gross marginadjusted gross margin to exceed 70%
- Noteat least a 35% Adjusted EBITDA margin
- Notefull year R&D expenses of between $10 and $14 million
- NoteThe revised Adjusted EBITDA guidance is inclusive of a $3 million licensing payment for ASN-001 which will be expensed in the third quarter
- NoteThe revised Adjusted EBITDA guidance is inclusive of a potential, one-time $4 million commercial milestone payment related to ALKINDI SPRINKLE sales performance, which may be triggered in the fourth quarter of 2026
What drove it
- The addition of revenue from HEMANGEOL and year-over-year growth across the portfolio, in particular INCRELEX, ALKINDI SPRINKLE, GALZIN and Carglumic Acid, drove revenue growth.
- Approximately 95% of existing HEMANGEOL patients successfully transitioned by the end of June.
- DESMODA, launched in March, continued to see strong adoption and patient growth.
- The adrenal franchise of ALKINDI SPRINKLE and KHINDIVI surpassed 600 active patients on therapy.
- INCRELEX growth was driven by appropriate dose optimization and sustained treatment.
- Second-quarter 2026 revenue included $2.9 million of revenue from INCRELEX and GALZIN sales outside the United States.
Concerns
- Adjusted gross margin decreased to 73% from 75% because higher INCRELEX sales outside the United States generate negative gross margin.
- Management expects a significant increase in second-half 2026 R&D expense from increased development activity, including the INCRELEX label harmonization study, the $3 million ASN-001 licensing expense, and ASN-001 bioavailability-study spending.
- The potential, one-time $4 million commercial milestone payment related to ALKINDI SPRINKLE sales performance may be triggered in the fourth quarter of 2026.
- ASN-001, AMGLIDIA, ET-700 and the INCRELEX label harmonization initiative remain subject to study, regulatory filing and approval outcomes.
What to watch
- Commercialization of IMPAVIDO, expected to begin in September 2026.
- AMGLIDIA bioavailability-study initiation later this month and the planned NDA submission by the end of 2026.
- Potential first-half 2027 approval of KHINDIVI's expanded indication following the submitted Prior Approval Supplement.
- ASN-001 bioavailability study and anticipated NDA submission in the second half of 2027.
- ET-700 pilot-study results and the potential initiation of a pivotal clinical study in early 2027.
- First patients dosed in the INCRELEX label harmonization study, targeted by the end of 2026.
Balance sheet and cash flow
- Cash and cash equivalents were $26.8 million as of June 30, 2026.
- Short-term debt, net of discount was $ 8,825 as of June 30, 2026.
- Long-term debt, net of current portion and debt discount and accrued exit fees was $ 19,078 as of June 30, 2026.
- Net cash from operating activities was $ 14,660 for the six months ended June 30, 2026.
- Net cash used in investing activities was $(15,070 ) for the six months ended June 30, 2026.
- Purchase of product licensing rights was $(15,000 ) for the six months ended June 30, 2026.
- Net cash from financing activities was $ 1,313 for the six months ended June 30, 2026.
- Change in cash and cash equivalents was $ 903 for the six months ended June 30, 2026.
Analysis
Eton reported record second-quarter revenue of $37.6 million, up 99% from $18.9 million in the prior-year period. Management attributed the increase to HEMANGEOL revenue and growth across the portfolio, specifically citing INCRELEX, ALKINDI SPRINKLE, GALZIN and Carglumic Acid. The HEMANGEOL patient transition was substantially completed, with approximately 95% of existing patients transitioned by the end of June, while the adrenal franchise surpassed 600 active patients on therapy.
Profitability improved materially. Gross profit was $25.4 million versus $11.9 million, while adjusted gross profit was $27.4 million and adjusted gross margin was 73%. The adjusted gross margin was below the prior-year 75% because sales of INCRELEX outside the United States generate negative gross margin. GAAP net income was $11.6 million, or $0.35 per diluted share, compared with a prior-year net loss of $2.6 million, or $0.10 per basic and diluted share. Adjusted EBITDA was $16.2 million, or 43% of revenue, compared with $3.1 million, or 16% of revenue.
The expense profile reflects both operating leverage and preparations for development activity. R&D expense fell to $1.0 million from $3.7 million, primarily because the prior-year period included the DESMODA NDA submission fee. G&A expense rose 20% to $11.6 million, driven by headcount growth and higher FDA program fees after the company no longer qualified for the orphan fee exemption. Management expects a significant rise in second-half R&D expense, including the $3 million ASN-001 licensing expense, ASN-001 bioavailability-study spending and the INCRELEX label harmonization study.
Capital deployment during the first half included $(15,000 ) for product licensing rights. Net cash from operating activities was $14,660 for the six months ended June 30, 2026, while cash and cash equivalents were $26.8 million at quarter end. The balance sheet also reported short-term debt, net of discount, of $ 8,825 and long-term debt, net of current portion and debt discount and accrued exit fees, of $ 19,078.
Management raised full-year 2026 revenue guidance to exceed $145 million from more than $120 million and increased its Adjusted EBITDA margin outlook to at least 35% from at least 30%. The revised Adjusted EBITDA outlook includes a $3 million ASN-001 licensing payment, incremental ASN-001 R&D costs and a potential, one-time $4 million ALKINDI SPRINKLE commercial milestone. Product and pipeline milestones include expected IMPAVIDO commercialization in September 2026, AMGLIDIA NDA submission by the end of 2026, potential first-half 2027 approval for expanded KHINDIVI labeling, and anticipated ASN-001 NDA submission in the second half of 2027.
Management, verbatim
Eton reported another outstanding quarter, delivering 99% year-over-year revenue growth, reflecting the strength of our rare disease portfolio and the exceptional execution of our team.
Sean Brynjelsen, CEO of Eton Pharmaceuticals
Given our first half performance and strong outlook for the remainder of the year, we’re pleased to again raise our annual revenue guidance and now expect at least $145 million of revenue this year.
Sean Brynjelsen, CEO of Eton Pharmaceuticals
Not in the filing
stated, not guessed- GAAP gross margin was not reported.
- Prior-quarter comparisons for quarterly revenue, profitability, expenses and EPS were not reported.
- Individual product revenue figures, including HEMANGEOL, DESMODA, ALKINDI SPRINKLE, KHINDIVI, INCRELEX, GALZIN and Carglumic Acid, were not reported.
- Formal reportable operating segments and segment revenue were not reported.
- Free cash flow was not reported.
- Quarterly operating cash flow was not reported.
- Share repurchases and dividends were not reported.
- Full-year operating-expense guidance, other than R&D expense guidance, was not reported.
- Full-year tax-rate guidance was not reported.
- A previous quarterly outlook document was not provided; therefore, no actual-versus-prior-guidance comparison is included.
AlphaAI analysis generated from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure was cross-checked against the filing text; consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.